Inhibiting a specific immune signaling pathway in the brain may reduce inflammation and seizure susceptibility, making it a potential new…
Articles by Margarida Maia, PhD
The first child has received ION337 in an open-label Phase 1/2 study, marking the start of clinical testing of this…
Enrollment has been completed in a Phase 3 clinical study of zorevunersen, an experimental treatment for Dravet syndrome…
Most children and adults living with Dravet…
Diseases that mimic Dravet syndrome symptoms are usually caused by mutations in genes other than SCN1A — the gene…
Beyond reducing seizures, add-on treatment with Fintepla (fenfluramine) may improve daily functioning in areas such as communication, attention, and awareness…
Astrocytes change how they connect and function in a mouse model of Dravet syndrome — even without visible brain…
Encoded Therapeutics has met with the U.S. Food and Drug Administration (FDA) and the two have aligned on the…
A clinical study showed that Soticlestat, when added to standard treatment, tended to reduce convulsive seizures in children and young…
Problems with sleep and body temperature regulation in Dravet syndrome are linked through the hypothalamus — the part of the…